I
12.70
0.29 (2.34%)
| Previous Close | 12.41 |
| Open | 12.46 |
| Volume | 348,703 |
| Avg. Volume (3M) | 1,103,340 |
| Market Cap | 1,584,578,944 |
| Price / Sales | 1.56 |
| Price / Book | 145.25 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | -5.30% |
| Operating Margin (TTM) | 25.56% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | -6.30% |
| Quarterly Earnings Growth (YOY) | -23.00% |
| Current Ratio (MRQ) | 0.880 |
| Operating Cash Flow (TTM) | 135.00 M |
| Levered Free Cash Flow (TTM) | 264.88 M |
| Return on Assets (TTM) | 12.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Indivior PLC | Bearish | - |
AIStockmoo Score
0.4
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 4.02% |
| % Held by Institutions | 89.09% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Jun 2025 | Announcement | Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users |
| 02 Jun 2025 | Announcement | Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained |
| 13 May 2025 | Announcement | Indivior to Participate in Upcoming Investor Events |
| 01 May 2025 | Announcement | New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy |
| 24 Apr 2025 | Announcement | Indivior Announces Q1 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |